Allarity Therapeutics, Inc.

Equities

ALLR

US0167445008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-10 pm EDT			5-day change	1st Jan Change
1.080 ^USD	+2.86%		+6.93%	-7.69%

Jul. 07	Allarity Therapeutics, Inc. Announces Chief Financial Officer Changes	CI
Jul. 07	Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer	CI

Allarity Therapeutics, Inc Announces Changes to Board of Directors

Published on 06/11/2025 at 16:05

Allarity Therapeutics, Inc. announced that Jesper Høiland has been appointed to join the Company?s Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity?s development over the past two years. Mr. Høiland is already well-acquainted with Allarity?s mission and operations, having served as a strategic consultant to the Company since October 2024.

Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk?s U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma.

Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
NOVO NORDISK A/S	455.55DKK	+2.82%	+3.18%	309B
ASCENDIS PHARMA A/S	176.49USD	+0.44%	+1.33%	10.64B
ALLARITY THERAPEUTICS, INC.	1.080USD	+2.86%	+6.93%	15.83M

Latest news about Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. Announces Chief Financial Officer Changes	Jul. 07	CI
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer	Jul. 07	CI
Allarity Therapeutics, Inc. Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic	Jun. 30	CI
Allarity Therapeutics Doses Second Patient in Phase 2 Ovarian Cancer Trial	Jun. 27	MT
Allarity Therapeutics, Inc. Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer	Jun. 27	CI
Allarity Therapeutics Announces Changes To Board Of Directors	Jun. 11	RE
Allarity Therapeutics, Inc Announces Changes to Board of Directors	Jun. 11	CI
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action	Jun. 04	CI
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer	Jun. 02	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 09	CI
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025.	May. 09	CI
Allarity Therapeutics, Inc. Presents Novel Drug Response Predictor--DRP®?-- for Daratumumab in Multiple Myeloma at AACR2025	Apr. 25	CI
Allarity Therapeutics, Inc. Announces Thomas H. Jensen Moves from Class I Director to Class III Director	Apr. 16	CI
Allarity Therapeutics Cash & Cash Receivable Balance Of $20.9 Million As Of Dec 31, Expected To Fund Operations, Including Clinical Activities Into 2027	Mar. 31	RE
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 31	CI
Allarity Therapeutics, Inc. Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients At the 2025 Annual Meeting for the Society of Gynecologic Oncology	Mar. 17	CI
Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission	Mar. 13	RE
Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures	Mar. 13	MT
Allarity Therapeutics, Inc. Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration	Mar. 06	CI
Allarity Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares.	Mar. 03	CI
Allarity Therapeutics, Inc. authorizes a Buyback Plan.	Mar. 02	CI
Allarity Therapeutics, Inc. to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward Fda Approval in Advanced Ovarian Cancer Patients	Feb. 24	CI
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer	Feb. 06	CI
Allarity Therapeutics, Inc. Reports Key Progress in Phase 2 Stenoparib Trial	Nov. 19	CI
Allarity Therapeutics, Inc. Reports Impairment of Intangible Assets for the Third Quarter Ended September 30, 2024	Nov. 14	CI

Chart Allarity Therapeutics, Inc.

Duration

Period

ALLR: Dynamic Chart

Company Profile

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

Employees

Sector

Biotechnology & Medical Research

Calendar

Nov. 11 - Q3 2025 Earnings Release (Projected)

More about the company